课题基金 / 基金详情

Immune Regulation by Deubiquitination

Immune Regulation by Deubiquitination
通过去泛素化进行免疫调节
批准号:
9982199
负责人:
Michael Croft
金额:
$45.0万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-19 至 2023-08-31

项目摘要

项目成果

Michael Croft的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 我们的长期目标是研究免疫调节中的泛素系统。我们发起了一项 脱泛素酶CyLD的新研究发现T细胞CyLD缺乏 调节细胞(Treg)通过增加IL-4的产生而引起慢性肺部炎症。 这些初步研究指出了CyLD调节Tregs的新机制。 调节细胞因子的产生,并强调了潜在的组织特异性方面 Treg函数。最近,我们发现CyLD在细胞周期中起到了正向调节作用。 淋巴组织中Treg向T滤泡调节性T细胞的分化这些 因此,初步研究为检验我们的中心假设提供了坚实的基础 泛素化/去泛素化系统在免疫调节中起着关键作用 通过以组织上下文相关的方式调节不同的T细胞亚群。在这里我们 计划通过提出两个具体目标来验证这一假设:目标1,在 目的2,研究CyLD在TFR中的作用。预期的结果将是 极大地提高了我们对蛋白质去泛素化途径的基础知识 免疫调节,将为人类疾病的治疗干预提供线索。
英文摘要
Project Summary Our long-term goal is to study the ubiquitin system in immune regulation. We initiated a new study of the deubiquitinating enzyme CYLD and found that deficiency of CYLD in T regulatory cells (Treg) caused chronic lung inflammation by increasing IL-4 production. These preliminary studies pointed to new mechanisms of CYLD regulation of Tregs, via modulating the cytokine production, and highlighted potential tissue-specific aspects of Treg function. Recently, we found that CYLD acts as a positive regulator in the differentiation of Treg to T follicular regulatory T cells (Tfr) in lymphoid tissues. These preliminary studies thus provide us with a solid basis for testing our central hypothesis that the ubiquitination/deubiquitination system plays a critical role in immune regulation via modulating different T cell subsets in tissue context-dependent manner. Here we plan to test this hypothesis by proposing two Specific Aims: Aim 1, to study CYLD in Treg regulation; and Aim 2, to study the role of CYLD in Tfr. The expected results will significantly advance our basic knowledge on the protein deubiquitination pathway in immune regulation, and will provide clues to therapeutic intervention of human diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TWEAK and Skin Inflammation
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
TWEAK and Skin Inflammation
海外基金